Welcome! Login | Register
 

Sunday Political Brunch—October 22 - Could There be a “Trump Effect” in 2018?—Sunday Political Brunch -- October 22 - Could…

25 Ways to Get Into the Halloween Spirit in New England—25 Ways to Get Into the Halloween Spirit…

Fecteau: Disrespecting Our Fallen Heroes—Fecteau: Disrespecting Our Fallen Heroes

Fit For Life: You are Capable of More Than You Know…—Fit For Life: You are Capable of More…

Two Arrested for Drug Dealing in Worcester—Two Arrested for Drug Dealing in Worcester

Holy Cross Football Visits Colgate Looking to Snap 4-Game Losing Streak—Holy Cross Football Visits Colgate Looking to Snap…

10 Great Things to do in Worcester This Weekend - October 20, 2017—10 Great Things to do in Worcester This…

Woman Found Guilty of 2015 Murder in University Park—Woman Found Guilty of 2015 Murder in University…

Finneran: Grandparents’ Grief—Finneran: Grandparents’ Grief

Pride Radio Set to Launch in Worcester—Pride Radio Set to Launch in Worcester

 
 

AG Announces $68.5 Million Settlement with AstraZeneca

Friday, March 11, 2011

 

Attorney General Peter Kilmartin announced today that a $68.5 million dollar settlement has been reached with AstraZeneca Pharmaceuticals.

This settlement, which is the largest ever multi-state consumer protection-based pharmaceutical settlement, is expected to bring $908,838 to the state.

The settlement stems from a complaint alleging that AstraZeneca used deceptive practices to market the antipsychotic drug Seroquel for off-label uses, according to the Attorney General. The company was accused of withholding information on the drug’s dangerous potential side effects, in addition to the negative results of scientific study done that tested the safety of the drug.

“This settlement shows the commitment of this office to protect consumers from deceptive marketing and advertising practices by big pharmaceutical companies,” Kilmartin said.

Company promises changes

AstraZeneca has promised to alter the way that it markets Seroquel, eliminating the misleading practices in question. Along with the $68.5 million payment, under the settlement AstraZeneca must comply with provisions addressing numerous concerns that an extensive 3-year investigation yielded. For example, AstraZeneca must have policies in place to ensure that sales personnel do not promote to health care providers who are unlikely to prescribe Seroquel for an FDA-approved use.

Other states participating in the investigation and settlement were: Florida, Illinois, Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Idaho, Iowa, Kansas, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Washington, West Virginia and Wisconsin.
 

 

Enjoy this post? Share it with others.

 
Delivered Free Every
Day to Your Inbox